CAS: 1000296-70-7

PF 03709270 is an oral prodrug of sulopenem with broad-spectrum antibacterial effects on gram-positive and gram-negative bacteria.

Sulopenem etzadroxil is an oral prodrug antibiotic, a derivative of the penem class. It is designed to combat bacterial infections, particularly those caused by multi-drug resistant pathogens. This compound is derived through synthetic chemical processes, optimizing its pharmacokinetic properties for oral administration, which enhances patient compliance compared to intravenous routes. The mode of action of sulopenem etzadroxil involves the inhibition of bacterial cell wall synthesis. It achieves this by binding to penicillin-binding proteins (PBPs), which are essential for the cross-linking of the bacterial cell wall during replication. By disrupting this process, sulopenem etzadroxil effectively inhibits bacterial growth, resulting in bactericidal activity against susceptible organisms. Sulopenem etzadroxil is primarily used in clinical settings to treat infections caused by multi-drug resistant Enterobacteriaceae and other gram-negative bacteria. Its application is critical in the ongoing effort to address antibiotic resistance, offering an effective oral option in settings where intravenous administration is impractical. This compound represents a significant advancement in the development of oral antibiotics targeting severe and resistant bacterial infections.